Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2013-08-14 Earnings Release
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2013, by Galectin Therapeutics Inc. It announces the results of operations and financial condition for the quarter ended June 30, 2013, referencing a press release attached as Exhibit 99.1. The text explicitly states that the information is being furnished under Item 2.02 of Form 8-K and that it is not filed as part of a registration statement. The document is short (3906 characters) and primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis itself. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. Therefore, the appropriate classification is Earnings Release (ER).
2013-08-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2013, by Galectin Therapeutics Inc. It includes a Regulation FD Disclosure and a press release as Exhibit 99.1. The text explicitly states that the information is being furnished and not filed, and it is a current report pursuant to the Securities Exchange Act of 1934. There are no financial statements or detailed financial data included, only a press release attachment. The document length is 2898 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS), since it is a general regulatory announcement and does not contain substantive financial data or detailed report content.
2013-08-12 English
PRIMARY DOCUMENT
Director's Dealing
2013-08-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a Regulation FD Disclosure with an attached press release dated August 5, 2013. The document explicitly states that the press release is being furnished and not filed, and no financial statements or exhibits other than the press release are included. The length is 2948 characters, which is relatively short and mainly contains the filing cover page and a brief description of the attached press release. There is no substantive financial data, management discussion, or detailed report content. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-08-05 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 24, 2013, for Galectin Therapeutics Inc. It includes a Regulation FD Disclosure and attaches a press release as Exhibit 99.1. The text explicitly states that the press release is being furnished and not filed, and the document does not contain financial statements or detailed financial data. The length is 2886 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of quarterly or annual financial results, management discussion, or audit information. The document serves as a current report to announce a press release under Regulation FD, which is a regulatory filing to disclose material information to the public. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as a full financial report or other specific filing type.
2013-07-24 English
PRIMARY DOCUMENT
Director's Dealing
2013-07-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.